BREAKING THE BARRIER: ADVANCING PHARMACOLOGICAL SOLUTIONS SUCH AS VP1-001 FOR THE MANAGEMENT OF CATARACT AND PRESBYOPIA

Pharmacological management of cataract and presbyopia has gained significant attention as a potential non-surgical approach for vision restoration. Cataract and presbyopia are among the most common age-related eye disorders. Cataract occurs due to progressive clouding of the eye’s lens caused by protein aggregation and oxidative stress, whereas presbyopia results from the gradual loss of lens elasticity, reducing the ability to focus on near objects. Recent research has focused on developing pharmacological agents that restore lens transparency and flexibility. One notable development is VP1-001, a pharmacologic chaperone that stabilizes lens crystallin proteins. Crystallins are essential for maintaining lens clarity and flexibility, but aging can cause these proteins to misfold and aggregate, leading to cataract formation. VP1-001 works by stabilizing damaged crystallins and preventing aggregation, thereby improving lens transparency. Studies conducted under PRISMA guidelines (2010–2024) highlight two main therapeutic mechanisms for presbyopia: miosis and lens softening. Miosis-based treatments constrict the pupil to increase depth of focus and improve near vision. The FDA approval of pilocarpine ophthalmic solution marked an important milestone in presbyopia treatment. Other combinations such as phentolamine-based formulations and carbachol–brimonidine have also shown promising results with mild side effects. Additionally, antioxidants like resveratrol, L-carnosine, quercetin, chlorogenic acid, curcumin, and disulfiram help protect the lens from oxidative stress. Advances in nanoparticle and lipid-based drug delivery systems have further improved drug bioavailability and ocular penetration, supporting the development of effective pharmacological therapies.